Literature DB >> 20349162

Elevated osteopontin expression and proliferative/apoptotic ratio in the colorectal adenoma-dysplasia-carcinoma sequence.

Gábor Valcz1, Ferenc Sipos, Tibor Krenács, Jeannette Molnár, Arpád V Patai, Katalin Leiszter, Kinga Tóth, Norbert Solymosi, Orsolya Galamb, Béla Molnár, Zsolt Tulassay.   

Abstract

Colorectal cancer progression is characterized by altered epithelial proliferation and apoptosis and by changed expression of tumor development regulators. Our aims were to determine the proliferative/apoptotic epithelial cell ratio (PAR) in the adenoma-dysplasia-carcinoma sequence (ADCS), and to examine its association with osteopontin (OPN), a previously identified protein product related to cancer development. One mm diameter cores from 13 healthy colons, 13 adenomas and 13 colon carcinoma samples were included into a tissue microarray (TMA) block. TUNEL reaction and Ki-67 immunohistochemistry were applied to determine the PAR. The osteopontin protein was also immunodetected. Stained slides were semiquantitatively evaluated using digital microscope and statistically analyzed with logistic regression and Fisher's exact test. The PAR continuously increased along the ADCS. It was significantly (p < 0.001) higher in cancer epithelium (8.84 ± 7.01) than in adenomas (1.40 ± 0.78) and in normal controls (0.89 ± 0.21) (p < 0.001). Also, significant positive correlation was observed between elevated PAR and the expression of osteopontin. Cytoplasmic OPN expression was weak in healthy samples. In contrast, cytoplasmic immunoreaction was moderately intensive in adenomas, while in colon cancer strong, diffuse cytoplasmic immune staining was detected. Increasing PAR and OPN expression along ADCS may help monitoring colorectal cancer progression. The significantly elevated OPN protein levels we found during normal epithelium to carcinoma progression may contribute to the increased fibroblast-myofibroblast transition determining stem cell niche in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20349162     DOI: 10.1007/s12253-010-9260-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  28 in total

Review 1.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

2.  Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitro.

Authors:  A Elgavish; C Prince; P L Chang; K Lloyd; R Lindsey; R Reed
Journal:  Prostate       Date:  1998-05       Impact factor: 4.104

3.  The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Y H Lin; H F Yang-Yen
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

Review 4.  The role of osteopontin in breast cancer: clinical and experimental studies.

Authors:  A B Tuck; A F Chambers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

5.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 6.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

7.  A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.

Authors:  Jianxin Dai; Bohua Li; Jinping Shi; Ling Peng; Dapeng Zhang; Weizhu Qian; Sheng Hou; Lei Zhao; Jie Gao; Zhiguo Cao; Jian Zhao; Hao Wang; Yajun Guo
Journal:  Cancer Immunol Immunother       Date:  2009-08-19       Impact factor: 6.968

8.  Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin.

Authors:  D S Bautista; J W Xuan; C Hota; A F Chambers; J F Harris
Journal:  J Biol Chem       Date:  1994-09-16       Impact factor: 5.157

Review 9.  Growth control mechanisms in normal and transformed intestinal cells.

Authors:  A W Burgess
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1998-06-29       Impact factor: 6.237

Review 10.  The colorectal adenoma-carcinoma sequence.

Authors:  A Leslie; F A Carey; N R Pratt; R J C Steele
Journal:  Br J Surg       Date:  2002-07       Impact factor: 6.939

View more
  4 in total

1.  Curcumin Veto the Effects of Osteopontin (OPN) Specific Inhibitor on Leukemic Stem Cell Colony Forming Potential via Promotion of OPN Overexpression.

Authors:  Saeed Mohammadi; Seyed H Ghaffari; Mojgan Shaiegan; Mahin Nikogoftar Zarif; Mohsen Nikbakht; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-07-01

2.  IS THERE A CLINICAL PATHOLOGICAL CORRELATION OF COLORECTAL ADENOCARCINOMA WITH THE IMMUNOHISTOCHEMICAL EXPRESSION OF OPN AND ABCB5?

Authors:  Diogo Francesco Castoldi; Osvaldo Malafaia; Pedro Helo Dos Santos-Neto; Tatiana Varella Postiglioni; Cecilia Vasconcelos; Fabiola Past Bremer; Leticia Elizabeth Augustin Czeczko; Martin Gasser; Ana Maria Waaga-Gasser; Carmen Australia Paredes Marcondes Ribas
Journal:  Arq Bras Cir Dig       Date:  2021-03-22

3.  Expression of Extracellular Matrix-Related Genes and Their Regulatory microRNAs in Problematic Colorectal Polyps.

Authors:  Margareta Žlajpah; Emanuela Boštjančič; Bojan Tepeš; Nina Zidar
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

4.  Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors.

Authors:  Kai-Hsi Hsu; Hung-Wen Tsai; Pin-Wen Lin; Yun-Shang Hsu; Pei-Jung Lu; Yan-Shen Shan
Journal:  World J Surg Oncol       Date:  2014-06-20       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.